Related Experiment Video
Updated: Jun 30, 2026
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Advanced Oxidative Protein Products Role in Multiple Sclerosis: a Systematic Review and Meta-analysis
Patrícia Rodrigues1, Guilherme Vargas Bochi1, Gabriela Trevisan2
1Graduated Program in Pharmacology, Federal University of Santa Maria (UFSM), Avenida Roraima, 1000, Building 21, Room 5207, Santa Maria, RS, 97105-900, Brazil.
Abstract:
Multiple sclerosis (MS) is an autoimmune-mediated disease that damages the central nervous system. MS pathophysiological features are not entirely understood, but the increase of reactive oxygen species (ROS) possibly causes myelin and oligodendrocyte degeneration. ROS-increased production generates new compounds through oxidative modifications, including advanced oxidative protein products (AOPPs). The AOPPs are oxidative stress biomarkers and inflammatory mediators commonly formed by hypochlorous acid oxidative action on albumin. Considering that AOPPs accumulation produces ROS and induces neuronal apoptosis, these may represent a new target for drug development to MS treatment and a possible biomarker to monitor the severity of the disease. Thus, this review aims to investigate if there is an alteration in the AOPPs levels in MS and its possible involvement in patient disability. The second objective is to analyze whether drugs or compounds used in MS treatment could modify the AOPPs levels. The protocol was registered in PROSPERO (CRD42020203268). The databases' search yielded 327 articles. We excluded 259 duplicated articles and evaluated 68 articles by the title and abstract. We full-text analyzed 17 articles and included 13 articles. The AOPPs levels were increased in not-treated MS patients. Furthermore, the increase in disability status was associated with AOPPs accumulation in not-treated MS patients. Additionally, the AOPPs levels were reduced in MS patients after treatment. Therefore, AOPPs seem to play a role in MS pathophysiology and may become a new target for drug development and help MS diagnosis or treatment follow-up.
Insights
Advanced oxidative protein products (AOPPs) are elevated in multiple sclerosis (MS) patients, correlating with disability. Treatment reduced AOPPs, suggesting AOPPs as a potential therapeutic target and biomarker for MS.
Area of Science:
- Neuroimmunology
- Oxidative Stress Research
- Biomarker Discovery
Background:
- Multiple sclerosis (MS) is a central nervous system autoimmune disease with unclear pathophysiology.
- Increased reactive oxygen species (ROS) may cause myelin and oligodendrocyte damage in MS.
- Advanced oxidative protein products (AOPPs) are biomarkers of oxidative stress and inflammation, potentially linked to MS.
Purpose of the Study:
- To investigate AOPPs level alterations in MS patients.
- To determine the association between AOPPs and MS patient disability.
- To analyze the effect of MS treatments on AOPPs levels.
Main Methods:
- Systematic review of scientific literature.
- Searched databases for articles on AOPPs and MS.
- Included 13 relevant studies after rigorous screening.
Main Results:
- AOPPs levels were significantly increased in untreated MS patients.
- Higher AOPPs accumulation correlated with increased disability in untreated MS patients.
- MS treatments led to a reduction in AOPPs levels.
Conclusions:
- AOPPs play a role in MS pathophysiology.
- AOPPs may serve as a novel therapeutic target for MS drug development.
- AOPPs show potential as biomarkers for MS diagnosis and treatment monitoring.
